Allergan Buys Liver Drug Maker Tobira, Sending Biotech Stocks UpBy
Premium of at least 498 percent over Tobira’s Monday close
Other liver drug stocks soar: Intercept, Galectin, Conatus
Allergan Plc’s agreement to buy Tobira Therapeutics Inc. for as much as $1.7 billion sent biotech stocks soaring Tuesday, as investors bet that buyers will emerge for other companies developing experimental treatments for a liver disease known as NASH.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.